跳至主要内容
临床试验/NCT06132165
NCT06132165已完成1 期

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Massachusetts General Hospital1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2024年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
13
试验地点
1
主要终点
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

研究概览

简要总结

This study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and a control site..

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult ≥18 years of age
  • Have a diagnosis of NF1 based on germline genetic testing or by meeting ≥ 2 the following criteria:
  • Family history of NF1
  • Six or more light brown ("cafe-au-lait") spots on the skin
  • Presence of two or more neurofibromas of any type, or one or more plexiform neurofibromas
  • Freckling under the arms or in the groin area
  • Two or more pigmented, benign bumps on the eye's iris (Lisch nodules)
  • A distinctive bony lesion: dysplasia (abnormal growth) of the sphenoid bone behind the eye, or dysplasia of long bones, often in the lower leg
  • Tumor on the optic nerve that may interfere with vision
  • Patients must be seeking treatment for cNF
  • Patients must have ≥ 6 paired cNF (3 to be treated and 3 untreated) that are visible and measure between 2-8mm in size. These must be in areas amenable to treatment and surveillance with digital photography.
  • cNF must be located on the trunk, arms or legs of the patient
  • Able and willing to comply with all visit, treatment and evaluation schedules and requirements
  • Able to understand and provide written informed consent

排除标准

  • Individuals who cannot give informed consent or adhere to study schedule.
  • Actively tanning during the course of the study.
  • Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists;
  • Known allergy to injectable anesthetics, deoxycholic acid or polidocanol.
  • Women who are pregnant.
  • Those with acute thromboembolic diseases.
  • Those with bleeding abnormalities or those who are currently being treated with antiplatelet or anticoagulant therapy.
  • Those with dysphagia.
  • Any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study.

研究组 & 干预措施

Kybella Injection

Active Comparator

干预措施: Deoxycholic Acid (Drug)

Asclera Injection

Active Comparator

干预措施: Polidocanol (Drug)

755nm laser

Active Comparator

干预措施: 755nm Alexandrite Laser (Device)

结局指标

主要结局

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

时间窗: 3 months after treatment

Device based treatment will be considered tolerable if \<40% of participants treated have a \>grade 2 adverse event (AE). A grade 2 AE is defined as an event that requires treatment.

次要结局

  • Patient Report Outcomes(For the 12 months after treatment)
  • Clinician Reported Outcomes(For the 12 months after treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Richard Rox Anderson, MD

Director, Wellman Center for Photomedicine

Massachusetts General Hospital

研究点 (1)

Loading locations...

相似试验